FDA

>

Latest News

Credit: Yurii Kibalnik | stock.adobe.com
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis

April 30th 2025

AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.

Asembia 2025: A General Landscape of the Pharmaceutical Industry
Asembia 2025: A General Landscape of the Pharmaceutical Industry

April 29th 2025

FDA Approves Akeso’s PD-1 Monoclonal Antibody for Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma
FDA Approves Akeso’s PD-1 Monoclonal Antibody for Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma

April 25th 2025

AbbVie Submits Biologics License Application to FDA for Novel Serotype E Botulinum Neurotoxin in Moderate to Severe Glabellar Lines
AbbVie Submits Biologics License Application to FDA for Novel Serotype E Botulinum Neurotoxin in Moderate to Severe Glabellar Lines

April 24th 2025

FDA Updates Prescribing Information for Bristol Myers Squibb’s Camzyos to Reduce Echocardiography Monitoring Requirements
FDA Updates Prescribing Information for Bristol Myers Squibb’s Camzyos to Reduce Echocardiography Monitoring Requirements

April 21st 2025

Video Interviews
Podcasts

More News